Glycoprotein IIb/IIIa inhibitors are used in the acute coronary syndromes and percutaneous coronary intervention as antiplatelet agents. However, these agents induce thrombocytopenia in approximately 1% to 5% of patients, and may lead to bleeding complications. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. We describe a case of acute profound thrombocytopenia due to on tirofiban treatment in a patient who underwent primary angioplasty.
BoersmaEHarringtonEAMoliternoDJWhiteHThérouxPVan de WerfF. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized trials. Lancet2002; 359: 189–198.
2.
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation1997; 96: 1445–1453.
3.
BougieDWWilkerPRWuitschickEDCurtisBRMalikMLevineS. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood2002; 100: 2071–2076.
4.
WarkentinTEKeltonJG. Temporal aspects of heparin induced thrombocytopenia. N Engl J Med2001; 344: 1286–1292.
5.
BennettCLConnorsJMCarwileJMMoakeJLBellWRTarantoloSR. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med2000; 342: 1773–1777.
